Nyxoah (NYXH) has released an update.
Nyxoah SA, a medical technology firm, has submitted the final module of its Premarket Approval application for the Genio system to the FDA, marking a significant step towards offering Genio to US patients with Obstructive Sleep Apnea. The Genio system, which is already CE marked in Europe for treating sleep apnea, is a battery-free hypoglossal neurostimulation therapy, and its approval in the US is anticipated by the end of 2024.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.
